CRISPR Cas9 Technology and Genetic Engineering

About conference

The Annual Congress on CRISPR Cas9 Technology and Genetic Engineering, scheduled for December 01–02, 2026, in Dubai, UAE, will bring together leading researchers, clinicians, academicians, biotechnology experts, and industry professionals from around the world to discuss the latest breakthroughs in genome editing and genetic engineering. The congress will provide a dynamic platform for sharing innovative research, emerging technologies, and clinical applications of CRISPR-Cas9, while fostering interdisciplinary collaborations that drive scientific progress. The scientific program will feature keynote presentations, plenary lectures, oral and poster sessions, workshops, and networking opportunities covering gene editing, precision medicine, agricultural biotechnology, regenerative medicine, synthetic biology, ethical considerations, and future innovations. This international gathering aims to inspire meaningful discussions and accelerate the translation of cutting-edge genetic research into real-world applications that benefit healthcare, agriculture, and environmental sustainability.

Sessions/Tracks

Track1: Plant and Animal Biotechnology 

Agricultural biotechnology, also known as agritech, is an area of agricultural science involving the use of scientific tools and techniques, including genetic engineering, molecular markers, molecular diagnostics, vaccines, and tissue culture, to modify living organisms: plants, animals, and microorganisms. Biotechnology is used in many ways in agriculture. Agricultural biotechnology companies work to supply farmers with tools to increase the yield of plant and animal products, while lowering the costs of production. Agricultural biotechnology can also include production of plants such as orchids for ornamental purposes and plants that can be used for fuel production (biofuels). To accomplish these goals, biotechnologists develop products to protect animals and crops from disease and help farmers identify the best animals and seeds to use in selective breeding programs. Animal biotechnology is a branch of biotechnology in which molecular biology techniques are used to genetically engineer (i.e. modify the genome of) animals in order to improve their suitability for pharmaceutical, agricultural or industrial applications.

Track2: Structural Biology and Bioinformatics

Structural bioinformatics is related to prediction and analysis of the three dimensional structure of macromolecules, for example, protein, DNA, RNA. It deals with the speculation of overall folds, Interactions, structure and functional relationship and molecular folding of tentatively solved structures and computationally predicted structures. Structural bioinformatics tools have been created, assessed, applied to answer particular inquiries concerning a wide scope of themes. It gives an invaluable structural context for preservation and mechanistic investigation leading to practical knowledge.

Track3: Cancer and stem cells

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, stem cells can differentiate into all the specialized cells—ectoderm, endoderm and mesoderm (see induced pluripotent stem cells)—but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.

Track4: Genome Editing Methods and Novel Tools

Geneticengineering is the manipulation of an organism's genome using biotechnology Principles. It is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species domains for the production of improved or novel organisms. Genetic engineering has applications in medicine, research, industry and agriculture and can be used on a wide range of plants, animals and microorganisms. Tissue engineering is the use of a integration of cells, engineering and materials principles,andsuitable biochemical and physicochemical factors to improve or replace biological tissues. It involves the use of a scaffold for the formation of new viable tissue for a medical purpose. Tissue engineering cover a broad range of applications,  that repair or replace portions of or whole tissues (i.e., bone, cartilage, blood vessels, bladder, skin, muscle etc.). The definition of regenerative medicine is often used same sense with tissue engineering, although those involved in regenerative medicine place more emphasis on the use of stem cells or progenitor cells to produce tissues.

Track5: Therapeutic Genome Editing 

Medical Biotechnology or Red Biotechnology is the use of living cells and cell materials to research and produce pharmaceutical and diagnostic products that help and prevent human diseases. Applications in pharmacology, gene therapy, stem cells, Tissue engineering. By discovering new drugs and vaccines, there have been improved and accelerated drug testing, better diagnostic capabilities, and the availability of foods which enhance nutritional values. It has applications in manufacture pharmaceuticals like enzymes, antibiotics and vaccines, and its use for molecular diagnostic. Today, the availability of “targeted therapies” for diseases and individuals should greatly improve drug safety and efficacy, and the development of predictive technologies may lead to a new era in disease prevention, especially in some of the world’s fast developing economies. This sound rationale holds great potential and promise in the field of medical biotechnology.

Track6: Genome editing and gene regulation in human health

“CRISPR” (pronounced “crisper”) stands for Clustered Regularly Interspaced Short Palindromic Repeats, which are the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology. In the field of genome engineering, the term “CRISPR” or “CRISPR-Cas9” is often used loosely to refer to the various CRISPR-Cas9 and -CPF1, (and other) systems that can be programmed to target specific stretches of genetic code and to edit DNA at precise locations, as well as for other purposes, such as for new diagnostic tools. With these systems, researchers can permanently modify genes in living cells and organisms and, in the future, may make it possible to correct mutations at precise locations in the human genome in order to treat genetic causes of disease. Other systems are now available, such as CRISPR-Cas13’s, that target RNA provide alternate avenues for use, and with unique characteristics that have been leveraged for sensitive diagnostic tools, such as SHERLOCK.

Track7: Genome editing and gene regulation in industrial bacterial biotechnology

CRISPR “spacer” sequences are transcribed into short RNA sequences (“CRISPR RNAs” or “crRNAs”) capable of guiding the system to matching sequences of DNA. When the target DNA is found, Cas9 – one of the enzymes produced by the CRISPR system – binds to the DNA and cuts it, shutting the targeted gene off. Using modified versions of Cas9, researchers can activate gene expression instead of cutting the DNA. These techniques allow researchers to study the gene’s function.

Research also suggests that CRISPR-Cas9 can be used to target and modify “typos” in the three-billion-letter sequence of the human genome in an effort to treat genetic disease.

Track8: Genome editing and gene regulation in industrial eukaryotic biotechnology

CRISPR-Cas9 is proving to be an efficient and customizable alternative to other existing genome editing tools. Since the CRISPR-Cas9 system itself is capable of cutting DNA strands, CRISPRs do not need to be paired with separate cleaving enzymes as other tools do. They can also easily be matched with tailor-made “guide” RNA (gRNA) sequences designed to lead them to their DNA targets. Tens of thousands of such gRNA sequences have already been created and are available to the research community. CRISPR-Cas9 can also be used to target multiple genes simultaneously, which is another advantage that sets it apart from other gene-editing tools.

Track9: CRISPR technologies beyond genome editing and gene regulation

The genomes of various organisms encode a series of messages and instructions within their DNA sequences. Genome editing involves changing those sequences, thereby changing the messages. This can be done by inserting a cut or break in the DNA and tricking a cell's natural DNA repair mechanisms into introducing the changes one wants. CRISPR-Cas9 provides a means to do so.

In 2012, two pivotal research papers were published in the journals Science and PNAS, which helped transform bacterial CRISPR-Cas9 into a simple, programmable genome-editing tool. 

The studies, conducted by separate groups, concluded that Cas9 could be directed to cut any region of DNA. This could be done by simply changing the nucleotide sequence of crRNA, which binds to a complementary DNA target. In the 2012 Science article, Martin Jinek and colleagues further simplified the system by fusing crRNA and tracrRNA to create a single "guide RNA." Thus, genome editing requires only two components: a guide RNA and the Cas9 protein.

Track10: Achieving efficient delivery and editing

CRISPR-Cas9 is proving to be an efficient and customizable alternative to other existing genome editing tools. Since the CRISPR-Cas9 system itself is capable of cutting DNA strands, CRISPRs do not need to be paired with separate cleaving enzymes as other tools do. They can also easily be matched with tailor-made “guide” RNA (gRNA) sequences designed to lead them to their DNA targets. Tens of thousands of such gRNA sequences have already been created and are available to the research community. CRISPR-Cas9 can also be used to target multiple genes simultaneously, which is another advantage that sets it apart from other gene-editing tools.

Track11: Horizons of CRISPR biology

CRISPR genome editing allows scientists to quickly create cell and animal models, which researchers can use to accelerate research into diseases such as cancer and mental illness. In addition, CRISPR is now being developed as a rapid diagnostic. To help encourage this type of research worldwide, scientists and their team have trained thousands of researchers in the use of CRISPR genome editing technology through direct education and by sharing more than 40,000 CRISPR components with academic laboratories around the world.

Track12: CRISPR technologies and society

CRISPR-Cas9 has become popular in recent years. CRISPR technology has also been applied in the food and agricultural industries to engineer probiotic cultures and to vaccinate industrial cultures (for yogurt, for example) against viruses. It is also being used in crops to improve yield, drought tolerance and nutritional properties. There is also the phenomenon of "off-target effects," where DNA is cut at sites other than the intended target. This can lead to the introduction of unintended mutations.  Furthermore, Scientists noted that even when the system cuts on target, there is a chance of not getting a precise edit. They called this "genome vandalism."

Market Analysis

The global CRISPR-Cas9 and genetic engineering market has experienced remarkable growth over the past decade, driven by rapid advancements in genome editing, increasing investments in biotechnology, and expanding applications across healthcare, agriculture, industrial biotechnology, and environmental sciences. CRISPR-Cas9 has emerged as one of the most transformative technologies in modern life sciences, enabling researchers to edit genes with unprecedented precision, efficiency, and affordability. As governments, research institutions, and biotechnology companies continue to invest in genomic innovation, the market is expected to witness sustained expansion throughout the coming years.

The growing prevalence of genetic disorders, cancer, rare diseases, and infectious diseases has significantly increased the demand for gene-editing technologies. CRISPR-Cas9 is playing a pivotal role in developing next-generation gene therapies, precision medicine, regenerative medicine, and cell-based therapies. In addition, pharmaceutical and biotechnology companies are increasingly integrating genome-editing technologies into drug discovery, biomarker identification, and personalized treatment strategies.

According to recent market reports, the global CRISPR technology market was valued at approximately USD 4.5–5.0 billion in 2025 and is projected to surpass USD 14 billion by 2030, growing at a compound annual growth rate (CAGR) of approximately 24–26%. This rapid expansion is fueled by increasing clinical trials, rising research funding, technological innovations, and broader adoption of CRISPR-based applications across multiple industries.

Genetic engineering continues to transform agricultural biotechnology by enabling the development of climate-resilient, disease-resistant, pest-resistant, and nutritionally enhanced crops. As global food demand continues to rise alongside climate-related challenges, genome-editing technologies are becoming essential tools for improving crop productivity, sustainability, and food security. The livestock sector is also benefiting from advances in genetic engineering through improved animal health, disease resistance, and breeding efficiency.

Healthcare remains the largest application segment, accounting for a significant share of the market. Gene therapy, oncology, rare disease treatment, immunotherapy, molecular diagnostics, and regenerative medicine continue to drive investment in CRISPR-based technologies. The increasing number of regulatory approvals for gene-editing clinical trials and collaborations between academic institutions and biotechnology companies is accelerating commercialization worldwide.

Technological innovations including base editing, prime editing, epigenome editing, single-cell genomics, AI-driven genomic analysis, and high-throughput DNA sequencing are further expanding the capabilities of CRISPR technologies. These next-generation platforms are improving editing accuracy while minimizing off-target effects, creating new opportunities for both research and clinical applications.

North America continues to dominate the global CRISPR and genetic engineering market due to substantial investments in biotechnology research, well-established genomic research centers, favorable funding opportunities, and the presence of leading biotechnology companies. Europe maintains a strong position through collaborative research initiatives, supportive regulatory frameworks, and significant public investment in life sciences. Meanwhile, the Asia-Pacific region is expected to register the fastest growth through 2030, driven by expanding biotechnology infrastructure, increased government funding, growing pharmaceutical manufacturing capabilities, and rising genomic research activities in countries such as China, Japan, South Korea, Singapore, and India.

The industry is witnessing an increasing number of strategic partnerships, licensing agreements, mergers, acquisitions, and venture capital investments. Leading biotechnology companies, pharmaceutical organizations, research institutes, and academic centers are collaborating to accelerate innovation, improve manufacturing capabilities, and expand the clinical application of genome-editing technologies.

As ethical considerations, regulatory developments, and clinical translation continue to shape the future of genome editing, international scientific collaboration has become increasingly important. The Annual Congress on CRISPR Cas9 Technology and Genetic Engineering provides an ideal global platform for researchers, clinicians, biotechnology professionals, industry leaders, and policymakers to exchange knowledge, present pioneering discoveries, discuss regulatory and ethical challenges, and foster collaborations that will advance precision genome editing and genetic engineering for the benefit of global healthcare, agriculture, and sustainable development.